Modafinil Improves Episodic Memory and Working Memory Cognition in Patients With Remitted Depression: A Double-Blind, Randomized, Placebo-Controlled Study

Muzaffer Kaser, Julia B Deakin, Albert Michael, Camilo Zapata, Rachna Bansal, Dragana Ryan, Francesca Cormack, James B Rowe, Barbara J Sahakian, Muzaffer Kaser, Julia B Deakin, Albert Michael, Camilo Zapata, Rachna Bansal, Dragana Ryan, Francesca Cormack, James B Rowe, Barbara J Sahakian

Abstract

Background: Cognitive dysfunction is a core feature of depression and tends to persist even after mood symptoms recover, leading to detrimental effects on clinical and functional outcomes. However, most currently available treatments have not typically addressed cognition. Modafinil has been shown to have beneficial effects on cognitive function and therefore has the potential to improve cognition in depression. The objective of this double-blind, placebo-controlled study was to investigate the effects of modafinil on cognitive functions in patients with remitted depression.

Methods: In total, 60 patients with remitted depression participated in the study. Cognitive functions were evaluated with tests of working memory, planning, attention, and episodic memory from the Cambridge Neuropsychological Test Automated Battery at the baseline session and after treatment. A double-blind, randomized, placebo-controlled, parallel groups design was used to assess the effects of single-dose (200 mg) modafinil (n = 30) or placebo (n = 30) on cognition and fatigue. The main outcome measures were neurocognitive test scores from the Cambridge Neuropsychological Test Automated Battery. Visual analogue scales for subjective feelings and fatigue were used as secondary measures.

Results: The modafinil group had significantly better performance on tests of episodic memory (p = .01, ηp2 = .10) and working memory (p = .04, ηp2 = .06). Modafinil did not improve planning or sustained attention.

Conclusions: This study suggested that modafinil (200 mg) could improve episodic memory and working memory performance in patients with remitted depression. Modafinil may have potential as a therapeutic agent to help remitted depressed patients with persistent cognitive difficulties.

Keywords: Cognition; Cognitive enhancer; Depression; Memory; Modafinil; Treatment.

Figures

Figure 1
Figure 1
(Left) Episodic memory performance according to the difficulty level is shown. The repeated measures analysis of variance, which controlled for baseline performance, demonstrated a main effect of modafinil (F = 6.199, p = .01, ηp2 = .10). (Right) The bar graph shows a significant difference between modafinil and placebo groups at the Paired Associates Learning (PAL) 12 shapes stage after controlling for baseline performance (F = 4.211, p = .02, ηp2 = .13).
Figure 2
Figure 2
(Left) Working memory performance according to the difficulty level is shown. Repeated measures analysis of variance, which controlled for baseline performance, showed a trend effect of modafinil (F = 3.023, p = .08, ηp2 = .05). (Right) The bar graph shows a significant difference between modafinil and placebo groups at the Spatial Working Memory (SWM) 12 boxes stage after controlling for baseline performance (F = 4.125, p = .04, ηp2 = .06).

References

    1. Conradi H.J., Ormel J., de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: A 3-year prospective study. Psychol Med. 2011;41:1165–1174.
    1. Jaeger J., Berns S., Uzelac S., Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006;145:39–48.
    1. Godard J., Baruch P., Grondin S., Lafleur M.F. Psychosocial and neurocognitive functioning in unipolar and bipolar depression: A 12-month prospective study. Psychiatry Res. 2012;196:145–153.
    1. Majer M., Ising M., Künzel H., Binder E.B., Holsboer F., Modell S. Impaired divided attention predicts delayed response and risk to relapse in subjects with depressive disorders. Psychol Med. 2004;34:1453–1463.
    1. Demyttenaere K., Donneau A.F., Albert A., Ansseau M., Constant E., Van Heeringen K. What is important in being cured from depression? Discordance between physicians and patients. J Affect Disord. 2015;174:390–396.
    1. Keefe R.S.E., McClintock S.M., Roth R.M., Doraiswamy P.M., Tiger S., Madhoo M. Cognitive effects of pharmacotherapy for major depressive disorder: A systematic review. J Clin Psychiatry. 2014;75:864–876.
    1. National Academies of Sciences, Engineering, and Medicine . National Academies Press; Washington, DC: 2015. Enabling Discovery, Development, and Translation of Treatments for Cognitive Dysfunction in Depression: Workshop Summary.
    1. Medicines and Health Products Regulatory Agency. Provigil summary of product characteristics. Available at: . Accessed May 18, 2015.
    1. Goss A.J., Kaser M., Costafreda S.G., Sahakian B.J., Fu C.H.Y. Modafinil augmentation therapy in unipolar and bipolar depression: A systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013;74:1101–1107.
    1. DeBattista C., Lembke A., Solvason H.B., Ghebremichael R., Poirier J. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol. 2004;24:87–90.
    1. Turner D.C., Robbins T.W., Clark L., Aron A.R., Dowson J., Sahakian B.J. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology. 2003;165:260–269.
    1. Müller U., Rowe J.B., Rittman T., Lewis C., Robbins T.W., Sahakian B.J. Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. Neuropharmacology. 2013;64:490–495.
    1. Battleday R.M., Brem A.K. Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review. Eur Neuropsychopharmacol. 2015;25:1865–1881.
    1. Turner D.C., Clark L., Dowson J., Robbins T.W., Sahakian B.J. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2004;55:1031–1040.
    1. Scoriels L., Jones P.B., Sahakian B.J. Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain. Neuropharmacology. 2013;64:168–184.
    1. Hasselbalch B.J., Knorr U., Kessing L.V. Cognitive impairment in the remitted state of unipolar depressive disorder: A systematic review. J Affect Disord. 2011;134:20–31.
    1. Bora E., Harrison B.J., Yücel M., Pantelis C. Cognitive impairment in euthymic major depressive disorder: A meta-analysis. Psychol Med. 2013;43:2017–2026.
    1. Rock P.L., Roiser J.P., Riedel W.J., Blackwell A.D. Cognitive impairment in depression: A systematic review and meta-analysis. Psychol Med. 2014;44:2029–2040.
    1. Park S.B., Coull J.T., McShane R.H., Young A.H., Sahakian B.J., Robbins T.W. Tryptophan depletion in normal volunteers produces selective impairments in learning and memory. Neuropharmacology. 1994;33:575–588.
    1. Shallice T. Specific impairments of planning. Philos Trans R Soc Lond B Biol Sci. 1982;298:199–209.
    1. Owen A.M., Sahakian B.J., Semple J., Polkey C.E., Robbins T.W. Visuo-spatial short-term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia. 1995;33:1–24.
    1. Owen A.M., Downes J.J., Sahakian B.J., Polkey C.E., Robbins T.W. Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia. 1990;28:1021–1034.
    1. Sahakian B.J., Morris R.G., Evenden J.L., Heald A., Levy R., Philpot M. A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson’s disease. Brain. 1988;111:695–718.

    1. Cambridge Cognition Ltd. (2011): CANTABeclipse test administration guide, Version 4.0.0.

    1. Richardson J.T. Eta squared and partial eta squared as measures of effect size in educational research. Educ Res Rev. 2011;6:135–147.
    1. Bremner J.D., Narayan M., Anderson E.R., Staib L.H., Miller H.L., Charney D.S. Hippocampal volume reduction in major depression. Am J Psychiatry. 2000;157:115–118.
    1. Schmaal L., Veltman D.J., van Erp T.G.M., Sämann P.G., Frodl T., Jahanshad N. Subcortical brain alterations in major depressive disorder: Findings from the ENIGMA Major Depressive Disorder working group. Mol Psychiatry. 2016;21:806–812.
    1. Fairhall S.L., Sharma S., Magnusson J., Murphy B. Memory related dysregulation of hippocampal function in major depressive disorder. Biol Psychol. 2010;85:499–503.
    1. de Rover M., Pironti V.A., McCabe J.A., Acosta-Cabronero J., Arana F.S., Morein-Zamir S. Hippocampal dysfunction in patients with mild cognitive impairment: A functional neuroimaging study of a visuospatial paired associates learning task. Neuropsychologia. 2011;49:2060–2070.
    1. Ferraro L., Antonelli T., O’Connor W.T., Tanganelli S., Rambert F., Fuxe K. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. NeuroReport. 1997;8:2883–2887.
    1. Joo E.Y., Tae W.S., Jung K.Y., Hong S.B. Cerebral blood flow changes in man by wake‐promoting drug, modafinil: A randomized double blind study. J Sleep Res. 2008;17:82–88.
    1. Thomas R.J., Kwong K. Modafinil activates cortical and subcortical sites in the sleep-deprived state. Sleep. 2006;29:1471–1481.
    1. Hunter M.D., Ganesan V., Wilkinson I.D., Spence S.A. Impact of modafinil on prefrontal executive function in schizophrenia. Am J Psychiatry. 2006;163:2184–2186.
    1. Arnsten A.F. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology. 2004;174:25–31.
    1. Minzenberg M.J., Carter C.S. Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33:1477–1502.
    1. Insel T., Cuthbert B., Garvey M., Heinssen R., Pine D.S., Quinn K. Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167:748–751.
    1. Beats B.C., Sahakian B.J., Levy R. Cognitive performance in tests sensitive to frontal lobe dysfunction in the elderly depressed. Psychol Med. 1996;26:591–604.
    1. Elliott R., Sahakian B.J., Herrod J.J., Robbins T.W., Paykel E.S. Abnormal response to negative feedback in unipolar depression: Evidence for a diagnosis specific impairment. J Neurol Neurosurg Psychiatry. 1997;63:74–82.
    1. Miskowiak K., Vinberg M., Christensen E.M., Kessing L.V. Vol. 66. 2012. Is there a difference in subjective experience of cognitive function in patients with unipolar disorder versus bipolar disorder? pp. 389–395. (Nord J Psychiatry).
    1. McIntyre R.S., Lophaven S., Olsen C.K. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17:1557–1567.
    1. Dotson V.M., Beydoun M.A., Zonderman A.B. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology. 2010;75:27–34.
    1. Bortolato B., Miskowiak K.W., Köhler C.A., Maes M., Fernandes B.S., Berk M. Cognitive remission: A novel objective for the treatment of major depression? BMC Med. 2016;14:9.
    1. Roiser J.P., Elliott R., Sahakian B.J. Cognitive mechanisms of treatment in depression. Neuropsychopharmacology. 2012;37:117–136.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir